BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 1, 2026
Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
Cardiovascular RSS Feed RSS

Doctor using Strokeviewer LVO on smartphone

FDA clears Nico.lab’s AI-powered Strokeviewer to speed stroke care

Dec. 3, 2020
By Annette Boyle
For the 795,000 Americans who suffer a stroke each year, time is brain. The U.S. FDA granted 510(k) clearance to a solution the developer says could cut time-to-treatment in stroke by an hour, preserving 3.6 years of healthy life. Nico.lab’s artificial intelligence-based CT scan analyzer, Strokeviewer LVO, uses an algorithm that enables faster triaging of stroke patients and enables physicians to see the location of occlusions in minutes.
Read More
Device image

Livanova agrees to sell heart valve business to Gyrus Capital

Dec. 3, 2020
By Liz Hollis
Livanova plc has inked an agreement with Gyrus Capital SA to divest its heart valve business. The sale has an enterprise value of €60 million (US$73 million) and is expected to wrap up in the first half of next year. The Livanova board has already given its unanimous assent for the deal. Livanova now expects to strengthen its focus on its neuromodulation and cardiovascular platforms.
Read More

EPA/DHA does not show benefit in patients with cardiovascular risk

Dec. 3, 2020

Novel rat models of doxorubicin-induced left ventricular dysfunction

Dec. 2, 2020

Investigators develop a swine model of abdominal aortic aneurysm

Dec. 2, 2020
Device closeup

Corwave secures grant for its manufacturing facility

Dec. 1, 2020
By Bernard Banga
PARIS – Corwave SA has obtained $600,000 as part of the Ile-de-France region's stimulus plan, to boost development of its Neptune cardiac support pump. This subsidy is part of the manufacturing recovery plan for the Ile-de-France region, aimed at very small enterprises (VSEs), small and medium-sized enterprises (SMEs) and mid-cap companies. In the midst of the COVID-19 pandemic, the Ile-de-France Region is supporting re-industrialization in a region that brings together 12.1 million inhabitants, or nearly 19% of the French population.
Read More
Artery and plaque

PICCOLETO II study resurrects balloon vs. stent debate for small coronary arteries

Dec. 1, 2020
By Mark McCarty
The drug-eluting balloon (DEB) has not displaced the drug-eluting stent (DES) for treatment of infarcts, but that may be changing with the results of the PICCOLETO II study.
Read More

New KCNT1 inhibitors identified at Praxis Precision Medicines

Dec. 1, 2020

BioWorld MedTech’s Cardiology Extra for Nov. 30, 2020

Nov. 30, 2020
By Liz Hollis
Keeping you up to date on recent developments in cardiology, including: Remote help to lower BP, control cholesterol; Improving screening for dual heart disease; Candidate shows promise in reducing heart failure.
Read More

Results of a phase Ib trial evaluating the microR-132 inhibitor CDR-132L in heart failure

Nov. 30, 2020
Previous 1 2 … 183 184 185 186 187 188 189 190 191 … 1007 1008 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Handshake with DNA, molecules

    Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

    BioWorld Science
    Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
  • Digital brain with dollar sign

    Investors bet on transformative BCI tech for neuro disorders

    BioWorld
    An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing